Halozyme Therapeutics Stock Forecast

Stock Analysis |
|
Risk Assessment |
|
Trading Strategy |
|
Halozyme Therapeutics stock price ended at $58.61 on Thursday, after gaining 0.86%
(Updated on Feb 13, 2025)
The Halozyme Therapeutics stock price gained 0.86% on the last trading day (Thursday, 13th Feb 2025), rising from $58.11 to $58.61. During the last trading day the stock fluctuated 1.60% from a day low at $57.79 to a day high of $58.72. The price has risen in 7 of the last 10 days and is up by 3.88% over the past 2 weeks. Volume fell on the last day by -13 thousand shares and in total, 848 thousand shares were bought and sold for approximately $49.73 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 23.78% during the next 3 months and, with a 90% probability hold a price between $68.04 and $82.67 at the end of this 3-month period.

HALO Signals & Forecast
The Halozyme Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $57.73 and $53.82. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Monday, November 18, 2024, and so far it has risen 37.68%. Further rise is indicated until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).
Support, Risk & Stop-loss for Halozyme Therapeutics stock
On the downside, the stock finds support just below today's level from accumulated volume at $49.00 and $47.79. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Halozyme Therapeutics finds support just below today's level at $49.00. If this is broken, then the next support from accumulated volume will be at $47.79 and $45.65.
In general the stock tends to have very controlled movements and with good liquidity the risk is considered very low in this stock. During the last day, the stock moved $0.93 between high and low, or 1.60%. For the last week the stock has had daily average volatility of 1.91%.
Our recommended stop-loss: $56.86 (-2.98%) (This stock has very low daily movements and this gives very low risk. The RSI14 is 76 and this increases the risk substantially. There is a buy signal from a pivot bottom found 58 days ago.)
Trading Expectations (HALO) For The Upcoming Trading Day Of Friday 14th
For the upcoming trading day on Friday, 14th we expect Halozyme Therapeutics to open at $58.37, and during the day (based on 14 day Average True Range), to move between $57.28 and $59.94, which gives a possible trading interval of +/-$1.33 (+/-2.27%) up or down from last closing price. If Halozyme Therapeutics takes out the full calculated possible swing range there will be an estimated 4.53% move between the lowest and the highest trading price during the day.
With no resistance above and support from accumulated volume @ $49.00, some $9.61 (16.40%) from the current price of $58.61, our system finds the risk reward attractive.
Earnings coming up
Halozyme Therapeutics will release earnings AMC on Tuesday, February 18, 2025.The consensus among the analysts for the expected earnings (EPS) is $1.17. We will update the financials statements for Halozyme Therapeutics, that can be found here as soon as the records are public. Our systems has calculated a possible swing of +/- 3.60% in the first trading day after earnings release.
Is Halozyme Therapeutics stock A Buy?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Halozyme Therapeutics stock to perform well in the short-term.
Current score:
4.934
Buy Candidate
Unchanged
Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.
Predicted Fair Opening Price
Predicted fair opening price on February 14, 2025 - $58.37 ( 0.407%).HALO Performance
Trading levels for HALO
Fibonacci Support & Resistance Levels
Level | Price | |
---|---|---|
R3 | 59.30 | 1.17% |
R2 | 58.94 | 0.569% |
R1 | 58.73 | 0.196% |
Price | 58.61 | |
S1 | 58.02 | -1.01% |
S2 | 57.80 | -1.38% |
S3 | 57.45 | -1.98% |
Accumulated Volume Support & Resistance Levels
Level | Price | |
---|---|---|
R3 | 0 | - |
R2 | 0 | - |
R1 | 0 | - |
Price | 58.61 | |
S1 | 49.00 | -16.40% |
S2 | 47.79 | -18.46% |
S3 | 45.65 | -22.11% |
FAQ
Click here for our free guide on how to buy Halozyme Therapeutics Stock.